|
13 Jan 2021 |
UroGen Pharma and MD Anderson Announce Strategic Research Collaboration to Advance Investigational Treatment for High-Grade Bladder Cancer
|
|
12 Jan 2021 |
Biond Biologics and Sanofi Enter into Global Licensing Agreement for BND-22, a Novel Immune Checkpoint Inhibitor Targeting the ILT2 Receptor
|
|
12 Jan 2021 |
DiosCURE to Develop Highly Specific Single-Chain Antibodies Against SARS-CoV-2, Lead Candidates Described in Science Publication
|
|
12 Jan 2021 |
Vir Biotechnology and GSK Announce NHS-Supported AGILE Study to Evaluate VIR-7832 in the Early Treatment of COVID-19
|
|
12 Jan 2021 |
AvantGen Announces Licensing of Its Anti-SARS-CoV-2 Antibodies to IGM Biosciences for COVID-19 Therapy Development
|
|
12 Jan 2021 |
Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene
|
|
11 Jan 2021 |
Lilly's Donanemab Slows Clinical Decline of Alzheimer's Disease in Positive Phase 2 Trial
|
|
11 Jan 2021 |
ATP and Biolojic Design Launch Aulos Bioscience to Develop Highly Differentiated IL-2 Antibody Approach to Fighting Cancer
|
|
11 Jan 2021 |
Sanofi to acquire Kymab, adding KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L
|
|
07 Jan 2021 |
Risankizumab (SKYRIZI®) Demonstrates Significant Improvements in Clinical Remission and Endoscopic Response in Two Phase 3 Induction Studies in Patients with Crohn's Disease
|
|
07 Jan 2021 |
REMD Biotherapeutics Completes Enrollment and Announces Top-line Results of a Phase 2 Clinical Study of Volagidemab (REMD-477) in Patients with Type 1 Diabetes
|
|
06 Jan 2021 |
Novel Treatment Pioneered by MSK Kids Researchers Receives FDA Approval for Patients with High-Risk Neuroblastoma
|
|
06 Jan 2021 |
Mersana Therapeutics Announces Corporate and Pipeline Updates and 2021 Goals and Anticipated Milestones
|
|
06 Jan 2021 |
Chemomab Announces Positive Phase Ib Results of its SPARK study testing CM-101 in NAFLD patients
|
|
06 Jan 2021 |
Y-Biologics signed License Agreement with 3D Medicines for T cell bispecific engager in Greater China territory
|
|
05 Jan 2021 |
Risankizumab (SKYRIZI®) Phase 3 Results Demonstrate Improvements in Disease Activity Across Joint and Skin Symptoms Among Psoriatic Arthritis Patients
|
|
05 Jan 2021 |
Harpoon Therapeutics Doses First Patient with HPN328, an Anti-DLL3 T Cell Engager for Treatment of Small Cell Lung Cancer and other DLL3-Associated Tumors
|
|
05 Jan 2021 |
F-star Therapeutics Announces First Patient Dosed in FS222 Phase 1 Clinical Trial
|
|
05 Jan 2021 |
Genmab Announces Phase 3 Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
|
|
05 Jan 2021 |
Innate’s First NK Cell Engager Selected by Sanofi as Drug Candidate for Development
|
|
05 Jan 2021 |
Tonix Pharmaceuticals and Massachusetts General Hospital (MGH) Enter into Research Collaboration on Tonix’s Third Generation anti-CD40-Ligand Monoclonal Antibody, TNX-1500, for the Treatment and Prevention of Kidney Transplant Rejection
|
|
05 Jan 2021 |
Provention Bio Announces U.S. FDA Filing of a Biologics License Application (BLA) and Priority Review for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-risk Individuals
|
|
05 Jan 2021 |
European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) as Adjuvant Treatment for Resected Esophageal or Gastroesophageal Junction Cancer Following Chemoradiotherapy
|
|
05 Jan 2021 |
European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Combined with Chemotherapy as First-Line Treatment in Metastatic Gastric Cancer, Gastroesophageal Junction Cancer and Esophageal Adenocarcinoma
|
|
05 Jan 2021 |
Genentech’s Novel Anti-TIGIT Tiragolumab Granted FDA Breakthrough Therapy Designation in Combination With Tecentriq for PD-L1-High Non-Small Cell Lung Cancer
|
